FDA Approved: KRAZATI — Original Application (Mirati Therapeutics, Inc)

View source ↗

Summary

The FDA approves KRAZATI (adagrasib) from Mirati Therapeutics under the original NDA for metastatic KRAS G12C-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KRAZATI (adagrasib)

Snippet

ORIG AP for KRAZATI (ADAGRASIB)